68Ga-DOTATATE-PET shows promise for diagnosis of recurrent or persistent medullary thyroid cancer: A systematic review
- 29 March 2022
- journal article
- review article
- Published by Elsevier in The American Journal of Surgery
- Vol. 224 (2) , 670-675
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid CarcinomaThyroid®, 2015
- Comparison of 68Ga-DOTATATE PET-CT, 18F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinomaNuclear Medicine Communications, 2015
- Cost-Effectiveness of FDG-PET/CT for Cytologically Indeterminate Thyroid Nodules: A Decision Analytic ApproachThe Journal of Clinical Endocrinology & Metabolism, 2014
- Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinomaNuclear Medicine Communications, 2012
- Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- Comparison of 68Ga-DOTATATE and 18F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinomaBiomedicine & Pharmacotherapy, 2008
- Diagnostic Accuracy of 18F-FDG PET in Restaging Patients with Medullary Thyroid Carcinoma and Elevated Calcitonin LevelsJournal of Nuclear Medicine, 2007
- Medullary thyroid carcinoma: Management of lymph node metastasesCurrent Treatment Options in Oncology, 2005
- Investigating and dealing with publication and other biases in meta-analysisBMJ, 2001